A Prospective Cohort Study of Myasthenia Gravis in China

Condition(s) studied

Investigational drug(s) / intervention(s)

Steroid Drug: Maintaining low-dose oral steroids

Withdraw all immunosuppresants: Withdraw all immunosuppresants

Study summary

The goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers. The main questions it aims to answer are:

1. Whether low-dose oral steroids may lead to a reduction in the recurrence rate among patients with MG.
2. To identify potential biomarkers that can predict disease progression and prognosis.

This study recruits well-controlled patients with MG. Based on patient preferences and considerations such as coexisting conditions (e.g., uncontrolled hypertension, diabetes, severe osteoporosis, obesity), the participants will be non-randomly divided into two groups: a maintenance steroid therapy group and a withdrawal group (withdraw all immunosuppresants). Subsequently, these groups of patients will undergo long-term follow-up assessments.

Eligibility

Primary outcome measure(s)

• Relapse of myasthenia gravis — Within two years after recruitment
  One of the following three is met: (1) MGFA Postintervention Status: failure to maintain MMS (minimal manifestations status) or better. (2) Myasthenia gravis activities of daily living (MG-ADL) score ≥ 3; (3) Re-administration of cholinesterase inhibitors was required after achieving Complete Stable Remission (CSR) on the MGFA Postintervention Status.

Trial sites (1)

More Peking Union Medical College Hospital trials in China

Other trials for the same condition